`________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`________________
`
`REGENERON PHARMACEUTICALS, INC.,
`Petitioner
`
`v.
`
`NOVARTIS PHARMA AG,
`NOVARTIS TECHNOLOGY LLC,
`NOVARTIS PHARMACEUTICALS CORPORATION,
`Patent Owners.
`
`________________
`
`Case: IPR2021-00816
`Patent No. 9,220,631
`________________
`
`DECLARATION OF NICHOLAS K. MITROKOSTAS IN SUPPORT OF
`PATENT OWNERS’ MOTION FOR PRO HAC VICE ADMISSION OF
`NICHOLAS K. MITROKOSTAS UNDER 37 C.F.R. § 42.10(c)
`
`Novartis Exhibit 2098.001
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`
`
`I, Nicholas K. Mitrokostas, declare as follows:
`
`1.
`
`I obtained a B.A. from Harvard College in 1999, and a J.D.
`
`from Georgetown University Law Center in 2003.
`
`2.
`
`I am currently a partner in the law firm of Goodwin Procter LLP, a
`
`position I have held since 2011. In my 17 years of law practice, I have focused
`
`primarily on representing clients in patent litigations involving the
`
`pharmaceutical and chemical arts in United States District Courts and the Court
`
`of Appeals for the Federal Circuit. Through this work, I have gained extensive
`
`experience as a litigating attorney, particularly in patent cases.
`
`3.
`
`I am a member in good standing of the Bars of the Commonwealth
`
`of Massachusetts and the State of New York. I am admitted to practice before
`
`the United States District Court for the District of Massachusetts. I am also
`
`admitted to practice before the United States Court of Appeals for the Ninth
`
`Circuit, the United States Court of Appeals for the Federal Circuit, and the
`
`Supreme Court of the United States.
`
`4. Within the last three years, I have not appeared pro hac vice
`
`before the Office. However, I have successfully applied to appear pro
`
`hac vice before the Office in the following past proceedings: IPR2017-
`
`00287, IPR2015-00643, IPR2015-00644, IPR2015-00830, IPR2015-
`
`01835, and IPR2015-01836.
`
`
`
`
`
`1
`
`
`Novartis Exhibit 2098.002
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`5.
`
`I have substantial familiarity with the subject matter at issue in
`
`this proceeding. I have developed a strong familiarity with U.S. Patent No.
`
`9,220,631 (“the ’631 patent”), its prosecution history, the general subject
`
`matter to which the ’631 patent is directed, and the prior art references relied
`
`upon by Petitioner. Furthermore, I have thoroughly reviewed the Petition and
`
`accompanying Exhibits submitted in this proceeding.
`
`6.
`
`I have never been suspended or disbarred from practice before
`
`any court or administrative body.
`
`7.
`
`I have never had an application for admission to practice before
`
`any court or administrative body denied.
`
`8.
`
`I have never been subject to any sanction or contempt
`
`citation imposed by any court or administrative body.
`
`9.
`
`I have read and will comply with the Office Patent Trial Practice
`
`Guide and the Board’s Rules of Practice for Trials set forth in part 42 of 37
`
`C.F.R.
`
`10.
`
`I agree to be subject to the USPTO Rules of Professional Conduct
`
`set forth in 37 C.F.R. §§ 11.101 et. seq. and disciplinary jurisdiction under 37
`
`C.F.R. § 11.19(a).
`
`11.
`
`I declare under penalty of perjury that the foregoing is true and
`
`correct. I further declare that all statements made herein of my own knowledge
`
`2
`
`Novartis Exhibit 2098.003
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`are true and that all statements made on information and belief are believed to
`
`be true; and further that these statements were made with the knowledge that
`
`willful false statements and the like so made are punishable by fine or
`
`imprisonment, or both, under section 1001 of title 18 of the United States Code,
`
`and that such willful false statements may jeopardize the validity of the
`
`application or any patent issued thereon.
`
`Executed on: December 22, 2021
`
`/Nicholas K. Mitrokostas/
`Nicholas K. Mitrokostas
`
`3
`
`Novartis Exhibit 2098.004
`Regeneron v. Novartis, IPR2021-00816
`
`